Our History & Milestones
Discover the Ferring story
The development of Ferring is the story of people and peptides. It is about the far-reaching vision of groundbreaking scientists to harness the fundamental role of peptide hormones in controlling many of the body’s key processes to develop medicine on the body’s own terms. And, it is about the vision of entrepreneurs with a spirit of adventure to make these medicines available throughout the globe.
An important breakthrough for Ferring came when Dr. Paulsen and his staff succeeded in producing synthetic peptide hormones (vasopressin and oxytocin) on an industrial scale, and became one of the first companies in the worldwide pharmaceutical industry.
Ferring became the only worldwide producer of vasopressin, a hormone whose structure was modified to form the basis of MINIRIN®, which has been Ferring’s flagship product for 20 years.
Frederik Paulsen changed the company name to Ferring. He had practical and rational reasons for renaming the company; he wanted a name that would be easy to understand and pronounce in as many countries as possible.
His reason for choosing ‘Ferring’ was deeply personal and demonstrated his close connections with his native island of Föhr, since the Friesian word ‘Ferring’ is the name given to the islanders living there.
In the spring Nordiske Hormonlaboratorie started the production of adrenocorticotrophic hormone (ACTH) on rented 60 square metres in an old factory building in Malmö, Sweden. The ACTH came from local hog pituitaries which were richer in ACTH than other domestic species and furthermore hog slaughterhouses in the region were well organised.
Eva Frandsen who had experience with other peptide hormones from her time in Stockholm with Pharmacia and Organon led the production after having set up the same production the previous year with partners in Copenhagen. She was soon assisted by Helmer Hagstam, who later on became Ferring’s head of production and technical director for many years.
The appearance of ACTH and the adrenal cortical hormones on the drug market was the beginning of antimmune therapy and offered new possibilities for treating antimmune diseases. This resulted in an enormous amount of work in clinical development of the ACTH and new indications were added steadily. Dr. Paulsen headed up this work and he benefited from his good connections with Swedish doctors during many years.
Dr. Frederik Paulsen and Eva Frandsen incorporated ‘Nordiske Hormonlaboratorie’, later to be named Ferring. The company wanted to be a Nordic enterprise that focused on hormones, including production, chemical and physiological research, and their application in medicine.
Dr. Paulsen had become assistant professor at the Pharmacological Institute at the University of Lund where he advised on pharmacological and clinical matters and marketing. Few years later he took over full time leadership of the company.